Healthcare entity
acquisition is the sole category represented across all 1 tracked stories. DuplexSeq is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. DuplexSeq is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 4.7 for the same window. Their average consequence score of 5 runs below the beat's 5.6 for that window. TwinStrand Biosciences appears in 1 tracked Healthcare story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TwinStrand Biosciences. Shared-story counts are live from our verified record — not editorial picks.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive DNA sequencing into its pre-clinical service portfolio. The move positions Scantox as a leader in next-generation genetic toxicology, offering 10,000x higher sensitivity than standard sequencing methods.
Source: prnewswire.com · prnewswire.com
TwinStrand Biosciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
